Sun Genomics, a San Diego, CA-based direct-to-consumer custom probiotics and gut health company, closed a $9.25m Series A funding.
The round was led by Pangaea Ventures with participation from Orion Fund, managed by K3 Ventures, and Emerging Technologies Partners. Additional investors include Danone Manifesto Ventures, SOSV, Human Longevity, and Nascita Ventures.
The company intends to use the funds for growth in the custom probiotics market, scale delivery across the U.S., enter international markets, and propel the publication of its studies in partnership with academic institutions.
Led by Sunny Jain, CEO and founder, Sun Genomics was founded in 2016 with the release of its flagship product Floré, a microbiome test and gut probiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product that is based on their unique gut profiles. As part of its growing line of gut health products, the company launched Floré Defense in July 2020, an all-natural formula to boost immunity and respiratory health.
In addition to the Series A close, Sun Genomics announces Dr. Jack Gilbert, PhD, as medical and scientific advisor, and Mayank Goel as vice president of growth.
- At the University of California, San Diego Center of Microbiome Innovation, Dr. Gilbert uses molecular analysis to test fundamental hypotheses in microbial ecology. He has authored more than 250 peer-reviewed publications and book chapters on metagenomics and approaches to ecosystem ecology.
- Prior to Sun Genomics, Goel led growth marketing and analytics at two successfully acquired travel startups – HotelTonight (acquired by Airbnb) and Pillow (acquired by Vrbo, Expedia Group). He has created data-driven personalized services leading to growing user retention and revenues. Goel brings a unique combination of growth strategy and data analytics to help Sun Genomics become the leader in custom probiotics.
FinSMEs
16/09/2020